SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
Por:
Gonzalez-Cao M, Puertolas T, Martinez-Vila C, Carrera C, Maldonado Seral C, Rodríguez-Jiménez P, Sequero S, Cerezuela-Fuentes P, Feltes Ochoa R, Muñoz E, Antoñanzas Basa M, Martín-Liberal J, Soria A, Francisco Rodriguez Moreno J, Marquez-Rodas I, Lopez Criado P, Luis Manzano J, Lopez-Castro R, Ayala de Miguel P, Villalobos L, Martin Algarra S, Gonzalez-Barrallo I, Boada A, García Castaño A, Puig S, Crespo G, Luna Fra P, Aguayo Zamora C, Feito Rodríguez M, Valles L, Drozdowskyj A, Gardeazabal J, Antonio Fernandez-Morales L, Rodrigo A, Cruz R, Yelamos O, Rubio B, Mujica K, Provencio M, Berrocal A
Publicada:
1 mar 2023
Ahead of Print:
1 dic 2022
Resumen:
Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ( "GRAVID ").Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021.Results One hundred-fifty cases were registered. Median age was 68 years (range 6-95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February-May 2020, August-November 2020, and December 2020-April 2021. The first wave had the highest number of registered cases and COVID-19 mortality.Conclusion Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection.
Filiaciones:
Gonzalez-Cao M:
Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, C/Sabino Arana, 5, 080028, Barcelona, Spain.
Puertolas T:
Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
Martinez-Vila C:
Fundación Althaia, Xarxa Assistencial Universitària de Manresa, Barcelona, Spain
Carrera C:
Dermatology Department, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Melanoma Group IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
Maldonado Seral C:
Hospital Universitario Central de Asturias, Oviedo, Spain
Rodríguez-Jiménez P:
Dermatology Department, Hospital Universitario la Princesa, Madrid, Spain
Sequero S:
Medical Oncology Department, Hospital San Cecilio, Granada, Spain
Cerezuela-Fuentes P:
Medical Oncology Department, Hospital Clinico Universitario Virgen Arrixaca, Murcia, Spain
Feltes Ochoa R:
Hospital Universitario La Paz, Madrid, Spain
Muñoz E:
Medical Oncology Department. Hospital, Universitari Vall d'Hebron, Barcelona, Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Antoñanzas Basa M:
Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
Martín-Liberal J:
Medical Oncology Department, Catalan Institute of Oncology (ICO) Hospitalet, Barcelona, Spain
Soria A:
Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain
Francisco Rodriguez Moreno J:
Medical Oncology Department, Centro Integral Oncologico HM Clara Campal, Madrid, Spain
Marquez-Rodas I:
Medical Oncology Department, Hospital General Universitario Gregorio Marañon and CIBERONC, Madrid, Spain
Lopez Criado P:
Medical Oncology Department, Hospital MD Anderson, Madrid, Spain
Luis Manzano J:
Medical Oncology Department, Catalonian Institute of Oncology (ICO-Badalona), Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Barcelona, Spain
Lopez-Castro R:
Medical Oncology Department, HCU Valladolid, Valladolid, Spain
Ayala de Miguel P:
Hospital San Pedro de Alcántara, Cáceres, Spain
Villalobos L:
Hospital Príncipe de Asturias, Alcalá de Henares, Spain
Martin Algarra S:
Medical Oncology Department, Clinica Universitaria de Navarra, Pamplona, Spain
Gonzalez-Barrallo I:
Hospital Clínico de Valencia, Valencia, Spain
Boada A:
Dermatology Department, Hospital Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Barcelona, Spain
García Castaño A:
Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain
Puig S:
Dermatology Department, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Melanoma Group IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
Crespo G:
Hospital Universitario de Burgos, Burgos, Spain
Luna Fra P:
Hospital Son Espases, Mallorca, Spain
Aguayo Zamora C:
Hospital Universitario Infanta Sofía, Madrid, Spain
Feito Rodríguez M:
Hospital Universitario La Paz, Madrid, Spain
Valles L:
Hospital General de Villalba, Madrid, Spain
Drozdowskyj A:
Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, C/Sabino Arana, 5, 080028, Barcelona, Spain
Gardeazabal J:
Hospital de Cruces, Bilbao, Spain
Antonio Fernandez-Morales L:
Hospital Parc Tauli, Sabadell, Spain
Rodrigo A:
Hospital Arnau de Vilanova, Lleida, Spain
Cruz R:
Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
Yelamos O:
Dermatology Department, Hospital Sant Pau, Barcelona, Spain
Rubio B:
Oncology Department, Hospital Quiron, Madrid, Spain
Mujica K:
Hospital Donostia, Donostia, Spain
Provencio M:
Hospital Puerta de Hierro, Madrid, Spain
Berrocal A:
Hospital Universitario General de Valencia, Valencia, Spain
Bronze, Green Published
FULL TEXT
 |
Published Version |
|
| No Accesible |
|